Welcome to the Newron Pharmaceuticals website.
We are a clinical-stage biopharmaceutical company. Our shares are listed on the SWX Swiss Exchange (NWRN). Our mission is to discover, develop and commercialise novel drugs to treat diseases of the Central Nervous System (CNS) and pain.
Discovering and developing innovative therapeutics for CNS disorders
Research & Drug Development
2002
Veneroni O.; Faravelli L.; Calabresi M.; Maj R.; Fariello R.G.; Salvati P.
NW-1029: a Potent Na+Channel Blocker in Animal Models of Inflammatory and Neurtopathic Pain.
XXXIIth Annual Meeting of the Society of Neuroscience, Orlando, Florida USA, November 2-7, 2002
Veneroni O.; Maj R.; Calabresi M.; Fariello R.G.; Salvati P. (SPON. Biella G.)
Antihyperalgesic Effect of NW-1029, a Novel Na+Channel Blocker in Animal Models of Inflammatory and Neuropatic Pain.
10th World Congress on Pain, San Diego CA, USA, August 17-22, 2002
Zecca L.; Fariello R.G.; Riederer P.; Sulzer D.; Gatti A.; Tampellini D.
The Absolute Concentration of Nigral Neuromelanin, Assayed by a New Sensitive Method, Increases Throughout the Life and is Dramatically Decreased in Parkinson's Disease.
FEBS Lett.; 510(3): 216-20, 2002